This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, recent events and analyst opinion, patent information, a 10-year disease incidence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Datamonitor Healthcare estimates that in 2017, there were 78,600 incident cases of Hodgkin’s lymphoma worldwide, and expects that number to increase to 86,000 incident cases by 2026.
• In the same year, there were approximately 272,100 five-year prevalent cases of Hodgkin’s lymphoma worldwide, which is expected to increase to 297,700 cases by 2026.
• The approved drugs in the Hodgkin’s lymphoma space target antibody-drug conjugate, cluster of differentiation 30/tumor necrosis factor receptor superfamily member 8, microtubules, DNA, the immune system, and programmed death-1 receptor/programmed death ligands. The majority of the approved drugs are administered via the intravenous route.
• The majority of the industry-sponsored drugs in active clinical development for Hodgkin’s lymphoma are in Phase II, with no drugs in Phase III.
• Therapies in the pipeline for Hodgkin’s lymphoma focus on a wide variety of targets. The majority of the pipeline drugs in development are administered via the oral or intravenous routes, with only one product being tested in an intratumoral formulation.
• High-impact upcoming events for drugs in the Hodgkin’s lymphoma space comprise topline Phase IIa trial results for AFM13, and topline Phase III trial results for Keytruda.
• The overall likelihood of approval of a Phase I hematologic asset is 10.1%, and the average probability a drug advances from Phase III is 57.7%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
• There have been 41 licensing and asset acquisition deals involving Hodgkin’s lymphoma drugs during 2014–19. The largest deal was the $2,855m strategic collaboration agreement in 2014 between Pfizer and Cellectis for the development of chimeric antigen receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets.
• The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for Hodgkin’s lymphoma have been in the early and mid-phases of development, with 94% of trials in Phase I–II, and only 6% in Phase III–IV.
• The US has a substantial lead in the number of Hodgkin’s lymphoma clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.
• Clinical trial activity in the Hodgkin’s lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin’s lymphoma, with 47 trials.
• Takeda leads industry sponsors with by far the highest number of clinical trials for Hodgkin’s lymphoma, followed by Merck & Co.